(R)-2-PROPYLOCTANOIC ACID
| Title | Journal |
|---|---|
| Asymmetric allylic alkylation of acyclic allylic ethers with organolithium reagents. | Chemistry (Weinheim an der Bergstrasse, Germany) 20120917 |
| Inhibition of the activation of hepatic stellate cells by arundic acid via the induction of cytoglobin. | Biochemical and biophysical research communications 20120831 |
| Direct regiospecific and highly enantioselective intermolecular α-allylic alkylation of aldehydes by a combination of transition-metal and chiral amine catalysts. | Chemistry (Weinheim an der Bergstrasse, Germany) 20120305 |
| Neurological diseases as primary gliopathies: a reassessment of neurocentrism. | ASN neuro 20120101 |
| Improvement of some physicochemical properties of arundic acid, (R)-(-)-2-propyloctanonic acid, by complexation with hydrophilic cyclodextrins. | International journal of pharmaceutics 20110715 |
| A systematic review of clinical trials of pharmacological interventions for acute ischaemic stroke (1955-2008) that were completed, but not published in full. | Trials 20100101 |
| S100b counteracts neurodegeneration of rat cholinergic neurons in brain slices after oxygen-glucose deprivation. | Cardiovascular psychiatry and neurology 20100101 |
| Effects of S100B on Serotonergic Plasticity and Neuroinflammation in the Hippocampus in Down Syndrome and Alzheimer's Disease: Studies in an S100B Overexpressing Mouse Model. | Cardiovascular psychiatry and neurology 20100101 |
| S100B Protein, A Damage-Associated Molecular Pattern Protein in the Brain and Heart, and Beyond. | Cardiovascular psychiatry and neurology 20100101 |
| Targeting S100B in Cerebral Ischemia and in Alzheimer's Disease. | Cardiovascular psychiatry and neurology 20100101 |
| PSAPP mice exhibit regionally selective reductions in gliosis and plaque deposition in response to S100B ablation. | Journal of neuroinflammation 20100101 |
| Immunohistochemical analysis of brain lesions using S100B and glial fibrillary acidic protein antibodies in arundic acid- (ONO-2506) treated stroke-prone spontaneously hypertensive rats. | Journal of neural transmission (Vienna, Austria : 1996) 20091001 |
| Inflammatory mechanisms in ischemic stroke: therapeutic approaches. | Journal of translational medicine 20090101 |
| Delayed treatment with arundic acid reduces the MPTP-induced neurotoxicity in mice. | Cellular and molecular neurobiology 20080501 |
| Acute astrocyte activation in brain detected by MRI: new insights into T(1) hypointensity. | Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism 20080301 |
| Application of the correlation of in vitro dissolution behavior and in vivo plasma concentration profile (IVIVC) for soft-gel capsules--a pointless pursuit? | Biological & pharmaceutical bulletin 20071101 |
| Pharmacokinetics of arundic acid, an astrocyte modulating agent, in acute ischemic stroke. | Journal of clinical pharmacology 20070401 |
| Expression of S100 protein and protective effect of arundic acid on the rat brain in chronic cerebral hypoperfusion. | Brain research 20070302 |
| Effect of arundic acid on serum S-100beta in ischemic stroke. | Journal of the neurological sciences 20061221 |
| Safety and tolerability of arundic acid in acute ischemic stroke. | Journal of the neurological sciences 20061221 |
| Arundic Acid ameliorates cerebral amyloidosis and gliosis in Alzheimer transgenic mice. | The Journal of pharmacology and experimental therapeutics 20060801 |
| [Role of the astrocyte-specific protein S100B in acute stroke]. | Nihon yakurigaku zasshi. Folia pharmacologica Japonica 20060601 |
| Neuroprotective effect of arundic acid, an astrocyte-modulating agent, in mouse brain against MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) neurotoxicity. | Neuropharmacology 20060301 |
| Could treatment with arundic acid (ONO-2506) increase vulnerability for depression? | Medical hypotheses 20060101 |
| Progressive neurodegenerative disease and pain. | IDrugs : the investigational drugs journal 20051201 |
| Modulation of astrocytic activation by arundic acid (ONO-2506) mitigates detrimental effects of the apolipoprotein E4 isoform after permanent focal ischemia in apolipoprotein E knock-in mice. | Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism 20050601 |
| Arundic acid (ONO-2506) ameliorates delayed ischemic brain damage by preventing astrocytic overproduction of S100B. | Current drug targets. CNS and neurological disorders 20050401 |
| Arundic acid, an astrocyte-modulating agent, protects dopaminergic neurons against MPTP neurotoxicity in mice. | Brain research 20041224 |
| Gateways to clinical trials. | Methods and findings in experimental and clinical pharmacology 20040401 |
| Attenuation of a delayed increase in the extracellular glutamate level in the peri-infarct area following focal cerebral ischemia by a novel agent ONO-2506. | Neurochemistry international 20040101 |
| ONO-2506. Ono. | Current opinion in investigational drugs (London, England : 2000) 20030701 |
| Protection of dopaminergic neurons with a novel astrocyte modulating agent (R)-(-)-2-propyloctanoic acid (ONO-2506) in an MPTP-mouse model of Parkinson's disease. | Journal of the neurological sciences 20030415 |
| Astrocytic activation and delayed infarct expansion after permanent focal ischemia in rats. Part II: suppression of astrocytic activation by a novel agent (R)-(-)-2-propyloctanoic acid (ONO-2506) leads to mitigation of delayed infarct expansion and early improvement of neurologic deficits. | Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism 20020601 |